Genomic Health Inc (GHDX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Genomic Health Inc (GHDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014017
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

Genomic Health Inc (GHDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genomic Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Genomic Health Inc, Medical Devices Deals, 2011 to YTD 2017 9
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Genomic Health Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Station X Raises US$5 Million In Second Round Of Venture Financing 11
Partnerships 12
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 12
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 14
Equity Offering 15
Genomic Health Files Registration Statement For Public Offering Of Shares To Raise Up To US$334 Million 15
Genomic Health Inc – Key Competitors 16
Genomic Health Inc – Key Employees 17
Genomic Health Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Nov 08, 2017: Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress 19
Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress 21
May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress 23
Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook 25
Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 27
Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance 29
May 04, 2016: Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results 31
Feb 10, 2016: Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results 33
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Genomic Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genomic Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genomic Health Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Genomic Health Inc, Medical Devices Deals, 2011 to YTD 2017 9
Genomic Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Station X Raises US$5 Million In Second Round Of Venture Financing 11
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 12
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 14
Genomic Health Files Registration Statement For Public Offering Of Shares To Raise Up To US$334 Million 15
Genomic Health Inc, Key Competitors 16
Genomic Health Inc, Key Employees 17
Genomic Health Inc, Other Locations 18
Genomic Health Inc, Subsidiaries 18

★海外企業調査レポート[Genomic Health Inc (GHDX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eli Lilly and Co (LLY):医療機器:M&Aディール及び事業提携情報
    Summary Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. It als …
  • freenet AG:企業のM&A・事業提携・投資動向
    freenet AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's freenet AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Horizon Discovery Group Plc (HZD):企業の財務・戦略的SWOT分析
    Summary Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers se …
  • General Electric Co (GE):企業の財務・戦略的SWOT分析
    General Electric Co (GE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Rio Grande Electric Cooperative, Inc.:発電所・企業SWOT分析
    Rio Grande Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Vonovia SE:企業の戦略・SWOT・財務分析
    Vonovia SE - Strategy, SWOT and Corporate Finance Report Summary Vonovia SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Isetan Mitsukoshi Holdings Ltd.:企業の戦略・SWOT・財務分析
    Isetan Mitsukoshi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Isetan Mitsukoshi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • bioLytical Laboratories Inc:企業の製品パイプライン分析
    Summary bioLytical Laboratories Inc (bioLytical) operates as a medical device company that develops and manufactures HIV diagnostic products. The company provides products such as insti HIV-1 and HIV-2 antibody test and insti HIV-1 and HIV-2 test controls. Its product line offers test result that tr …
  • Gritstone Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Gritstone Oncology Inc (Gritstone) is a cancer immunotherapy company that focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neo-antigens from individual patients’ tumors for the development of novel …
  • Centinel Spine Inc:医療機器:M&Aディール及び事業提携情報
    Summary Centinel Spine Inc (Centinel Spine) is a medical device company that manufactures and markets spinal devices. The company develops integrated interbody fusion technologies. It offers lumbar and cervical solutions. Centinel Spine’s product includes ALTOS, a posterior cervical thoracic stabili …
  • Cebu Air Inc:戦略・SWOT・企業財務分析
    Cebu Air Inc - Strategy, SWOT and Corporate Finance Report Summary Cebu Air Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Range Resources Corporation:企業の戦略・SWOT・財務情報
    Range Resources Corporation - Strategy, SWOT and Corporate Finance Report Summary Range Resources Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Sanmina Corporation (SANM):企業の財務・戦略的SWOT分析
    Sanmina Corporation (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • EyeGate Pharmaceuticals Inc (EYEG)-医療機器分野:企業M&A・提携分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient a …
  • Cedar Fair, L.P.:企業の戦略・SWOT・財務情報
    Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report Summary Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Otsuka Corp (4768):企業の財務・戦略的SWOT分析
    Otsuka Corp (4768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Onxeo SA (ONXEO):企業の財務・戦略的SWOT分析
    Summary Onxeo SA (Onxeo) is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as beleodaq and asidna among others. It offers drugs for the treatment of liver cancer, and treatment and pr …
  • Associated Alcohols & Breweries Limited.:企業の戦略・SWOT・財務情報
    Associated Alcohols & Breweries Limited. - Strategy, SWOT and Corporate Finance Report Summary Associated Alcohols & Breweries Limited. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Dowa Holdings Co., Ltd.:戦略・SWOT・企業財務分析
    Dowa Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dowa Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Cynvenio Biosystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cynvenio Biosystems Inc (Cynvenio) is a cancer diagnostic company that focuses on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood. The company offers products such as lab automation systems, isolation products and proprietary informat …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆